Cargando…

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension

There was no structured method for safely transition from parenteral prostanoids to oral medication. We enrolled 37 idiopathic/hereditary pulmonary arterial hypertension patients receiving triple combination therapy including parenteral prostanoids into structured transition program to oral selexipa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Yuichi, Furukawa, Asuka, Tamura, Yudai, Yamada, Kenta, Taniguchi, Hirohisa, Fukuda, Keiichi, Kawamura, Akio, Satoh, Toru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052976/ https://www.ncbi.nlm.nih.gov/pubmed/35506073 http://dx.doi.org/10.1002/pul2.12058

Ejemplares similares

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Usefulness of Global Longitudinal Strain-Guided Management in Preventing Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor-Induced Myocardial Damage
por: Yamada, Kenta, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Case Report: BMPR2-Targeted MinION Sequencing as a Tool for Genetic Analysis in Patients With Pulmonary Arterial Hypertension
por: Takashima, Tomoya, et al.
Publicado: (2021)

Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Tamura, Yudai, et al.
Publicado: (2022)

How COVID-19 Affected the Introduction of Telemedicine and Patient Reported Outcomes Among Patients With Pulmonary Hypertension　― A Report From a Referral Center in Japan ―
por: Tamura, Yuichi, et al.
Publicado: (2020)

Pulmonary hypertension associated with neurofibromatosis type 2
por: Taniguchi, Hirohisa, et al.
Publicado: (2021)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Case report: Pathological differences in pulmonary arterial hypertension in long-term responders to calcium channel blockers
por: Tamura, Yuichi, et al.
Publicado: (2023)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Current clinical understanding and effectiveness of portopulmonary hypertension treatment
por: Tamura, Yuichi, et al.
Publicado: (2023)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2011)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension　― Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers ―
por: Ishiguro, Midori, et al.
Publicado: (2020)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
por: Scelsi, Laura, et al.
Publicado: (2021)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
por: Kimura, Mai, et al.
Publicado: (2015)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_88cekscov1fk97rhcuct56knu3